The Clinical Value of Computed Tomography (CT)-Guided ¹²⁵I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

References

• Carney DN, Hansen HH. Non-small-cell lung cancer-stalemate or progress? N Engl J Med. 2000;343(17):1261–1262. doi:10.1056/NEJM20001026343171011071679
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Takenoyama M, Ichinose Y. Multimodality treatment with surgery for locally advanced non-small-cell lung cancer with N2 disease: a review article. Clin Lung Cancer. 2015;16(1):6–14. doi:10.1016/j.cllc.2014.07.00725220209
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK positive non–small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi:10.1056/NEJMoa170479528586279
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi:10.1016/S1470-2045(11)70184-X21783417
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa160677427718847
   PubMed Web of Science ®Google Scholar
• Planting A, Helle P, Drings P, et al. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC lung cancer cooperative group trial. Ann Oncol. 1996;7(2):139–144. doi:10.1093/oxfordjournals.annonc.a0105408777169
   PubMed Web of Science ®Google Scholar
• Morton RF, Jett JR, McGinnis WL, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, Phase III trial. Ann Intern Med. 1991;115(9):681–686. doi:10.7326/0003-4819-115-9-6811656827
   PubMed Web of Science ®Google Scholar
• Cardenal F, Nadal E, Jove M, et al. Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature. Ann Oncol. 2015;26(2):278–288. doi:10.1093/annonc/mdu22924942274
   PubMed Web of Science ®Google Scholar
• Vrankar M, Stanic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol. 2018;52(3):281–288. doi:10.2478/raon-2018-000930210037
   PubMed Web of Science ®Google Scholar
• Jassem J. Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer. Lancet Oncol. 2001;2(6):335–342. doi:10.1016/S1470-2045(00)00387-911905749
   PubMed Web of Science ®Google Scholar
• Ramella S, Fiore M, Silipigni S, et al. Local control and toxicity of adaptive radiotherapy using weekly CT imaging: results from the LARTIA trial in stage III NSCLC. J Thorac Oncol. 2017;12(7):1122–1130. doi:10.1016/j.jtho.2017.03.02528428149
   PubMed Web of Science ®Google Scholar
• Cannon DM, Mehta MP, Adkison JB, et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4343–4348. doi:10.1200/JCO.2013.51.535324145340
   PubMed Web of Science ®Google Scholar
• Monk BJ, Tewari KS, Puthawala AA, Syed AM, Haugen JA, Burger RA. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys. 2002;52(3):806–815. doi:10.1016/S0360-3016(01)02728-611849805
   PubMed Web of Science ®Google Scholar
• Jin Z, Du Y, Li Z, et al. Endoscopic ultrasonography-guided interstitial implantation of iodine 125-seeds combined with chemotherapy in the treatment of unresectable pancreatic carcinoma: a prospective pilot study. Endoscopy. 2008;40(04):314–320. doi:10.1055/s-2007-99547618283622
   PubMed Web of Science ®Google Scholar
• Hu X, Qiu H, Zhang L, et al. Recurrent gliomas: comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy. Cancer Biol Ther. 2012;13(10):840–847. doi:10.4161/cbt.2083422797010
   PubMed Web of Science ®Google Scholar
• Xiang Z, Bai M, Li G, et al. Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation. J Cancer Res Clin Oncol. 2019;145(7):1907–1916. doi:10.1007/s00432-019-02943-x31161374
   PubMed Web of Science ®Google Scholar
• Xiang Z, Li G, Liu Z, et al. 125I brachytherapy in locally advanced nonsmall cell lung cancer after progression of concurrent radiochemotherapy. Medicine (Baltimore). 2015;94(49):e2249. doi:10.1097/MD.000000000000224926656370
   PubMed Web of Science ®Google Scholar
• Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44(4):789–799. doi:10.1016/S0360-3016(99)00069-310386635
   PubMed Web of Science ®Google Scholar
• Yan H, Xiang Z, Zhong Z, et al. CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region. Transl Oncol. 2017;10(1):90–98. doi:10.1016/j.tranon.2016.11.00727992832
   PubMed Web of Science ®Google Scholar
• Mo Z, Zhang T, Zhang Y, et al. Feasibility and clinical value of CT-guided 125I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure. Eur Radiol. 2018;28(3):1194–1203. doi:10.1007/s00330-017-5036-028956119
   PubMed Web of Science ®Google Scholar
• Ruysscher DD, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009;20(1):98–102. doi:10.1093/annonc/mdn55918718891
   PubMed Web of Science ®Google Scholar
• Moreno-Jimenez M, Aristu J, Lopez-Picazo JM, et al. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation. Radiother Oncol. 2008;88(3):342–350. doi:10.1016/j.radonc.2008.05.01918558448
   PubMed Web of Science ®Google Scholar
• Qu A, Wang H, Li J, et al. Biological effects of 125I seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death. Cancer Invest. 2014;32(6):209–217. doi:10.3109/07357907.2014.90558524745612
   PubMed Web of Science ®Google Scholar
• Zhou D, Shao L, Spitz DR. Reactive oxygen species in normal and tumor stem cells. Adv Cancer Res. 2014;122:1–67.24974178
   PubMed Web of Science ®Google Scholar
• Yang G, Peng S, Zhang Y, et al. Cell-based assay system to estimate the effect of 125I seeds on cancer cells: effect of osteopontin. Recent Pat Anticancer Drug Discov. 2014;9(2):258–263. doi:10.2174/157489280966614033115174724693996
   PubMed Web of Science ®Google Scholar
• Yan H, Mo Z, Xiang Z, et al. CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. J Cancer. 2017;8(11):2104–2113. doi:10.7150/jca.1907828819412
   PubMed Web of Science ®Google Scholar
• Zhang T, Lu M, Peng S, et al. CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol. 2014;140(8):1383–1390. doi:10.1007/s00432-014-1655-x24723151
   PubMed Web of Science ®Google Scholar
• Zhang S, Zheng Y, Yu P, et al. The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer. J Cancer Res Clin Oncol. 2011;137(12):1813–1822. doi:10.1007/s00432-011-1048-321922327
   PubMed Web of Science ®Google Scholar
• Wu C, Li B, Sun G, Peng C, Xiang D. Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly. Onco Targets Ther. 2018;11:6617–6624. doi:10.2147/OTT.S17445730349295
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561–1571. doi:10.1016/S0140-6736(13)62159-524576776
   PubMed Web of Science ®Google Scholar
• Maeda R, Yoshida J, Hishida T, et al. Late recurrence of non-small cell lung cancer more than 5 years after complete resection: incidence and clinical implications in patient follow-up. Chest. 2010;138(1):145–150. doi:10.1378/chest.09-236120382716
   PubMed Web of Science ®Google Scholar
• Sen E, Kaya A, Erol S, Savas I, Gonullu U. Kadinlarda akciğer kanseri: klinik özellikler ve sağkalima etkili faktörler [Lung cancer in women: clinical features and factors related to survival]. Tuberk Toraks. 2008;56(3):266–274.18932027
   PubMedGoogle Scholar
• Smith IE, O’Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001;19(5):1336–1343. doi:10.1200/JCO.2001.19.5.133611230476
   PubMed Web of Science ®Google Scholar
• Di Maio M, Gridelli C, Gallo C, et al. Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer. 2004;90(12):2288–2296. doi:10.1038/sj.bjc.660181015162156
   PubMed Web of Science ®Google Scholar
• Nag S. Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations. Semin Urol Oncol. 2000;18(2):133–136.10875454
   PubMedGoogle Scholar